Biotech Values

[DewDiligence]

>More rivaroxaban success<

This is the same study for which top-line data were reported in May.

As I’ve posted on various occasions, Xarelto (rivaroxaban) has all the makings of a very big-selling drug. However, it remains to be seen whether a pure FXa inhibitor—as opposed to a drug that inhibits both FXa and FIIa—can work well enough in arterial thrombosis indications such as ACS to become a new standard of care.